What is SI-BONE?
Headquartered in Santa Clara, California, SI-BONE is a global medical device innovator dedicated to the development of sacropelvic solutions. Since its inception in 2008, the company has focused on the commercialization of its iFuse Technology, a minimally invasive surgical approach designed to treat SI joint dysfunction, pelvic trauma, and spinopelvic fixation. By providing surgeons with advanced, evidence-based tools, SI-BONE has effectively carved out a niche in the orthopedic landscape, addressing a significant patient population that was previously underserved by traditional surgical methods. The company's market position is defined by its rigorous clinical research, proprietary technology, and a clear focus on improving patient outcomes through specialized, high-precision instrumentation.
How much funding has SI-BONE raised?
SI-BONE has raised a total of $399.4M across 10 funding rounds:
Unspecified
$16M
Private Equity
$33M
Private Equity
$21M
Debt
$39.2M
Private Equity
$20M
Stock Offering
$124.2M
Stock Offering
$53.5M
Debt
$40M
Debt
$51M
Unspecified (2011): $16M led by Skyline Ventures and Montreux Equity Partners
Private Equity (2014): $33M supported by Montreux Equity Partners, OrbiMed, Skyline Ventures, and Novo A/S
Private Equity (2015): $21M featuring Montreux Equity Partners, OrbiMed, Redline Capital Management, and Skyline Ventures
Debt (2015): $39.2M backed by Oxford Finance and Silicon Valley Bank
Private Equity (2016): $20M with participation from Redline Capital Management, OrbiMed, Montreux Equity Partners, Arboretum Ventures, Skyline Ventures, and Novo A/S
Stock Issuance/Offering (2018): $124.2M, investors not publicly disclosed
Stock Issuance/Offering (2020): $53.5M, investors not publicly disclosed
Debt (2020): $40M featuring Solar Capital Partners
Debt (2023): $51M backed by Silicon Valley Bank
Key Investors in SI-BONE
Skyline Ventures
A nationally-known venture capital firm specializing in product-focused healthcare companies, including medical devices and diagnostics, led by professionals with deep clinical and operational expertise.
Montreux Equity Partners
A growth-oriented investment firm that focuses on scaling commercial-stage companies by providing strategic capital to category-leading healthcare and technology businesses.
OrbiMed
A specialized healthcare investment firm with extensive expertise across biopharmaceuticals and medical devices, known for its multi-stage strategy that supports companies from early development to market maturity.
What's next for SI-BONE?
Looking ahead, the strategic deployment of the $51M capital is expected to accelerate SI-BONE's operational scale and market penetration. As the company transitions from its foundational growth phase into a more mature, enterprise-level entity, the focus will likely shift toward expanding its clinical evidence base and optimizing its commercial infrastructure. The continued support from institutional investors suggests a strong confidence in the company's long-term trajectory. Future initiatives will likely prioritize the integration of new digital health tools and the expansion of its product portfolio to address broader spinopelvic pathologies, ensuring that SI-BONE remains at the forefront of medical innovation in the musculoskeletal space.
See full SI-BONE company page
